Surgical treatment of gastric, enteric, and pancreatic endocrine tumors: Part 1. Treatment of primary endocrine tumors;Traitement chirurgical des tumeurs endocrines gastro-entéro- pancréatiques: 1. Traitement des tumeurs primitives

Journal de Chirurgie

Volumn 142, Issue 3, 2005, Pages 132-149

  Kianmanesh, R ^a,b   O'Toole, D ^a   Sauvanet, A ^a   Ruszniewski, P ^a   Belghiti, J ^a  

^a BEAUJON HOSPITAL   (France)

^b HÔPITAL LOUIS MOURIER   (France)

Author keywords

Carcinoid tumor; Endocrine carcinoma; Pancreas; Small intestine; Stomach; Treatment; Zollinger ellison

Indexed keywords

EID: 22744435432     PISSN: 00217697     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0021-7697(05)80881-6     Document Type: Review

References (236)

1. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934-959.
2. Jensen RT. Natural history of digestive endocrine tumors. In Mignon M, Colombel JF (eds). "Recent Advances in the pathology and management of inflammatory bowel disease and digestive endocrine tumors." Paris: 1999;192-219.
3. Baudin E, Ducreux M, Sabourin JC et al. Les tumeurs neuroendocrines gastro-entéropancréatiques. Médecine Thérapeutique Endocrinologie 1999;1:165-174.
4. Ruszniewski P, O'Toole D. Clinical spectrum of digestive neuroendocrine tumors. Rev Prat 2002;52:262-267.
5. Moertel CG, Weiland LH, Nagorney DM, Dockerty MB. Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med 1987;317:1699-1701.
6. Moertel CG, Johnson CM, McKusick MA et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 1994;120:302-309.
7. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999;340:858-868.
8. Sarmiento JM, Heywood G, Rubin J et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003;197:29-37.
9. Jensen RT. Current diagnosis and management of gastrointestinal neuroendocrine tumours. Dig Liver Dis 2001;33:212-214.
10. Norton JA, Warren RS, Kelly MG et al. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 2003;134:1057-1063.
11. Madeira I, Terris B, Voss M et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 1998;43:422-427.
12. Madeira I, Ruszniewski P. Digestive system carcinoid tumors: treatment. Rev Med Interne 1999;20: 421-426.
13. Schlumberger M, Baudin E. Neuroendocrine tumors. Ann Endocrinol (Paris) 1997;58:95-99.
14. Ducreux M, Baudin E, Schlumberger M. Treatment strategy of neuroendocrine tumors. Rev Prat 2002;52:290-296.
15. Elias D, Lasser P, Ducreux M et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery 2003;133: 375-382.
16. Mignon M. Natural history of neuroendocrine enteropancreatic tumors. Digestion 2000;62 Suppl 1:51-58.
17. Partensky C. Prise en charge des tumeurs endocrines duodéno- pancréatiques. J Chir (Paris) 2000;137:142-150.
18. Maggard MA, O'Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg 2004;240:117-122.
19. Oberg K. Diagnosis and treatment of carcinoid tumors. Expert Rev Anticancer Ther 2003;3:863-877.
20. Baudin E, Gigliotti A, Ducreux M et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 1998;78:1102-1107.
21. Jensen RT. Pancreatic endocrine tumors: recent advances. Ann Oncol 1999;10 Suppl 4:170-176.
22. Calender A. Genetics of neuroendocrine tumors. Rev Prat 2002;52: 256-261.
23. Saint-Andre JP, Dupre F, Chenue F, Guyetant S. Histopathology of neuroendocrine tumors. Ann Endocrinol (Paris) 1997;58:101-111.
24. Mitry E, Baudin E, Ducreux M et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999;81:1351-1355.
25. Mitry E, Rougier P. Treatment strategy for pancreatic endocrine tumours. Gastroenterol Clin Biol 2003;27:S31-S36.
26. O'Toole D, Kianmanesh R, Farges O, Ruszniewski P. Treatment of pancreaticduodenal endocrine tumors. Rev Prat 2002;52:1546-1553.
27. Ahlman H. Surgical treatment of carcinoid tumours of the stomach and small intestine. Ital J Gastroenterol Hepatol 1999;31 Suppl 2: S198-S201.
28. Plockinger U, Wiedenmann B. Neuroendocrine tumors of the gastro-entero-pancreatic system: the role of early diagnosis, genetic testing and preventive surgery. Dig Dis 2002;20:49-60.
29. O'Toole D, Maire F, Ruszniewski P. Ablative therapies for liver metastases of digestive endocrine tumours. Endocr Relat Cancer 2003;10:463-468.
30. Ruszniewski P, Terris B. Natural history and prognosis of pancreatic endocrine tumors. Gastroenterol Clin Biol 2003;27:S20-S25.
31. Roche A, Lasser P. Locoregional therapy of neuroendocrine tumors. Rev Prat 2002;52:274-278.
32. Sutliff VE, Doppman JL, Gibril F et al. Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns. J Clin Oncol 1997;15:2420-2431.
33. Weber HC, Venzon DJ, Lin JT et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995;108:1637-1649.
34. Jaeck D, Oussoultzoglou E, Bachellier P et al. Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: safe hepatic surgery. World J Surg 2001;25:689-692.
35. Que FG, Sarmiento JM, Nagorney DM. Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors. Cancer Control 2002;9:67-79.
36. Chu QD, Hill HC, Douglass HO, Jr. et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol 2002;9: 855-862.
37. Calender A, Giraud S, Porchet N et al. [Clinicogenetic study of MEN1: recent physiopathological data and clinical applications. Study Group of Multiple Endocrine Neoplasia (GENEM)]. Ann Endocrinol (Paris) 1998;59:444-451.
38. Aubert-Petit G, Baudin E, Cailleux AF et al. Neuro-endocrine tumors and von Hippel-Lindau disease. 3 cases. Presse Med 1999;28:1231-1234.
39. Chandrasekharappa SC, Guru SC, Manickam P et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997; 276:404-407.
40. Agarwal SK, Lee BA, Sukhodolets KE et al. Molecular pathology of the MEN1 gene. Ann N Y Acad Sci 2004;1014:189-198.
41. Calender A, Cadiot G, Mignon M. Multiple endocrine neoplasia type 1: genetic and clinical aspects. Gastroenterol Clin Biol 2001;25: B38-B48.
42. Brandi ML, Gagel RF, Angeli A et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86: 5658-5671.
43. Goudet P, Peschaud F, Mignon M et al. [Gastrinomas in multiple endocrine neoplasia type-1. A 127-case cohort study from the endocrine tumor group (GTE)]. Ann Chir 2004;129: 149-155.
44. Hammel P, Beigelman C, Chauveau D et al. [Variety of pancreatic lesions observed in von Hippel-Lindau disease. Apropos of 8 cases]. Gastroenterol Clin Biol 1995;19: 1011-1017.
45. Hammel PR, Vilgrain V, Terris B et al. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Étude de la Maladie de von Hippel-Lindau. Gastroenterology 2000;119:1087-1095.
46. Eriksson B, Oberg K. Neuroendocrine tumours of the pancreas. Br J Surg 2000;87:129-131.
47. Guth A. Tumeurs endocrines du pancréas. In Vilgrain V, Menu Y (eds): «Imagerie du foie, des voies biliaires, du pancréas et de la rate.» Paris: Flammarion, 2002;349-359.
48. Baudin E, Dromain C. Biology and imaging of neuroendocrine tumors. Rev Prat 2002;52:268-273.
49. Pereira PL, Wiskirchen J. Morphological and functional investigations of neuroendocrine tumors of the pancreas. Eur Radiol 2003;13:2133-2146.
50. Kirshbom PM, Kherani AR, Onaitis MW et al. Carcinoids of unknown origin: comparative analysis with foregut, midgut, and hindgut carcinoids. Surgery 1998;124:1063-1070.
51. Akerstrom G. Management of carcinoid tumors of the stomach, duodenum, and pancreas. World J Surg 1996;20:173-182.
52. Couvelard A, Felce-Dachez M, Degott C. Histological classification of endocrine tumors of the pancreas. Gastroenterol Clin Biol 2003;27: S15-S19.
53. Phan GQ, Yeo CJ, Hruban RH et al. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gastrointest Surg 1998;2: 472-482.
54. Lam KY, Lo CY. Pancreatic endocrine tumour: a 22-year clinico-pathological experience with morphological, immunohistochemical observation and a review of the literature. Eur J Surg Oncol 1997;23: 36-42.
55. Dromain C, de Baere T, Baudin E et al. MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR Am J Roentgenol 2003;180: 121-128.
56. Azimuddin K, Chamberlain RS. The surgical management of pancreatic neuroendocrine tumors. Surg Clin North Am 2001;81:511-525.
57. Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 2003;12:231-242.
58. Akerstrom G, Makridis C, Johansson H. Abdominal surgery in patients with midgut carcinoid tumors. Acta Oncol 1991;30:547-553.
59. Akerstrom G. Aspects on surgical strategy in midgut carcinoids and endocrine pancreatic tumors. In Mignon M, Colombel JF (eds): «Recent advances in the pathophysiology and management of inflammatory bowel disease and digestive endocrine tumors.» Paris: 1999;330-334.
60. Partensky C, Berger F, Owono P et al. [Cephalic duodenopancreatectomy for endocrine tumor of the ampulla of Vater and of the minor papilla]. Gastroenterol Clin Biol 1999;23:832-836.
61. Sauvanet A, Partensky C, Sastre B et al. Medial pancreatectomy: a multi-institutional retrospective study of 53 patients by the French Pancreas Club. Surgery 2002;132:836-843.
62. Ricke J, Klose KJ. Recommendations for standardised imaging in neuroendocrine tumours. In Mignon M, Colombel JF (eds): «Recent advances in the pathophysiology and management of inflammatory bowel disease and digestive endocrine tumors.» Paris: 1999;298-301.
63. Ricke J, Klose KJ, Mignon M et al. Standardisation of imaging in neuroendocrine tumours: results of a European delphi process. Eur J Radiol 2001;37:8-17.
64. Rodallec M, Vilgrain V, Zins M et al. Helical CT of pancreatic endocrine tumors. J Comput Assist Tomogr 2002: 26:728-733.
65. Zins M, Sauvanet A. Diagnosis of pancreatic tumors. Rev Prat 2002; 52:1525-1531.
66. Ichikawa T, Peterson MS, Federle MP et al. Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. Radiology 2000;216:163-171.
67. Kalra MK, Maher MM, Mueller PR, Saini S. State-of-the-art imaging of pancreatic neoplasms. Br J Radiol 2003;76:857-865.
68. Palazzo L, Roseau G, Salmeron M. Endoscopic ultrasonography in the preoperative localization of pancreatic endocrine tumors. Endoscopy 1992;24 Suppl 1:350-353.
69. O'Toole D, Palazzo L, Ruszniewski P. Role of endoscopic ultrasonography in endocrine tumours of the duodenopancreatic region. In Mignon M, Colombel JF (eds): "Recent Advances in the pathology and management of inflammatory bowel disease and digestive endocrine tumors." Paris: 1999;229-240.
70. Gauger PG, Scheiman JM, Wamsteker EJ et al. Role of endoscopic ultrasonography in screening and treatment of pancreatic endocrine tumours in asymptomatic patients with multiple endocrine neoplasia type 1. Br J Surg 2003;90:748-754.
71. Chiti A, Fanti S, Savelli G et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med 1998;25:1396-1403.
72. de Herder WW, Hofland LJ, van der Lely AJ, Lamberts SW. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer 2003;10:451-458.
73. van der Lely AJ, de Herder WW, Krenning EP, Kwekkeboom DJ. Octreoscan radioreceptor imaging. Endocrine 2003;20:307-311.
74. Proye C, Malvaux P, Pattou F et al. Noninvasive imaging of insulinomas and gastrinomas with endoscopic ultrasonography and somatostatin receptor scintigraphy. Surgery 1998; 124:1134-1143.
75. Voss M, Hammel P, Molas G et al. Value of endoscopic ultrasound guided fine needle aspiration biopsy in the diagnosis of solid pancreatic masses. Gut 2000;46:244-249.
76. Fidler JL, Johnson CD. Imaging of neuroendocrine tumors of the pancreas. Int J Gastrointest Cancer 2001;30:73-85.
77. Régent D. Tumeur endocrine du pancréas. In Régent D, Schmutz G, Génin G (eds). «Imagerie du foie, des voies biliaires et du pancréas.» Paris: 1994;174-176.
78. Simon D, Starke A, Goretzki PE, Roeher HD. Reoperative surgery for organic hyperinsulinism: indications and operative strategy. World J Surg 1998;22:666-671.
79. Hiramoto JS, Feldstein VA, LaBerge JM, Norton JA. Intraoperative ultrasound and preoperative localization detects all occult insulinomas ; discussion 1025-6. Arch Surg 2001;136:1020-1025.
80. Norton JA, Alexander HR, Fraker DL et al. Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome? Ann Surg 2004;239:617-625.
81. Norton JA. Gastrinoma: advances in localization and treatment. Surg Oncol Clin N Am 1998;7:845-861.
82. Norton JA. Intra-operative procedures to localize endocrine tumours of the pancreas and duodenum. Ital J Gastroenterol Hepatol 1999;31 Suppl 2:S195-S197.
83. Thompson GB. Diagnosis and management if insulinomas. Endocr Pract 2002;8:385-386.
84. Norton JA, Shawker TH, Doppman JL et al. Localization and surgical treatment of occult insulinomas. Ann Surg 1990;212:615-620.
85. Norton JA, Fraker DL, Alexander HR et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999;341:635-644.
86. Farley DR, van Heerden JA, Grant CS, Thompson GB. Extrapancreatic gastrinomas. Surgical experience. Arch Surg 1994;129:506-511.
87. Grant CS. Gastrointestinal endocrine tumours. Insulinoma. Baillieres Clin Gastroenterol 1996;10:645-671.
88. Correnti S, Liverani A, Antonini G et al. Intraoperative ultrasonography for pancreatic insulinomas. Hepatogastroenterology 1996;43:207-211.
89. Jordan PH, Jr. A personal experience with pancreatic and duodenal neuroendocrine tumors. J Am Coll Surg 1999;189:470-482.
90. Chapuis Y, Bigourdan JM, Massault PP et al. [Videolaparoscopic excision of insulinoma. A study of 5 cases]. Chirurgie 1998;123:461-467.
91. Mabrut JY, Boulez J, Peix JL et al. Laparoscopic pancreatic resections. Ann Chir 2003;128:425-432.
92. Jaroszewski DE, Schlinkert RT, Thompson GB, Schlinkert DK. Laparoscopic localization and resection of insulinomas. Arch Surg 2004;139:270-274.
93. Masson B, Sa-Cunha A, Laurent G et al. [Laparoscopic pancreatectomy: report of 22 cases]. Ann Chir 2003;128:452-456.
94. Ikeda S, Matsumoto S, Maeshiro K et al. Segmental pancreatectomy for the diagnosis and treatment of small lesions in the neck or body of the pancreas. Hepatogastroenterology 1995;42:730-733.
95. Rotman N, Fagniez PL. Medial pancreatectomy. J Hepatobiliary Pancreat Surg 2000;7:453-455.
96. Pradère B, Carrère N, Gonzi JL. Les pancréatectomies gauches. JChir 1999;136:324-331.
97. Iihara M, Kanbe M, Okamoto T et al. Laparoscopic ultrasonography for resection of insulinomas. Surgery 2001;130:1086-1091.
98. Fernandez-Cruz L, Saenz A, Astudillo E et al. Outcome of laparoscopic pancreatic surgery: endocrine and nonendocrine tumors. World J Surg 2002;26:1057-1065.
99. Gramatica L, Jr., Herrera MF, Mercado-Luna A et al. Videolaparoscopic resection of insulinomas: experience in two institutions. World J Surg 2002;26:1297-1300.
100. Barlehner E, Anders S, Schwetling R. Laparoscopic resection of the left pancreas: technique and indication. Dig Surg 2002;19:507-510.
101. Park AE, Heniford BT. Therapeutic laparoscopy of the pancreas. Ann Surg 2002;236:149-158.
102. Finlayson E, Clark OH. Surgical treatment of insulinomas. Surg Clin North Am 2004;84:775-785.
103. Sauvanet A. Functional results of pancreatic surgery. Rev Prat 2002; 52:1572-1575.
104. Fabre JM, Houry S, Manderscheid JC et al. Surgery for left-sided pancreatic cancer. Br J Surg 1996;83:1065-1070.
105. Benoist S, Dugue L, Sauvanet A et al. Is there a role of preservation of the spleen in distal pancreatectomy? J Am Coll Surg 1999;188:255-260.
106. Brigden ML, Pattullo A, Brown G. Pneumococcal vaccine administration associated with splenectomy: the need for improved education, documentation, and the use of a practical checklist. Am J Hematol 2000;65:25-29.
107. Sumaraju V, Smith LG, Smith SM. Infectious complications in asplenic hosts. Infect Dis Clin North Am 2001;15:551-65.
108. Lynch AM, Kapila R. Overwhelming postsplenectomy infection. Infect Dis Clin North Am 1996; 10:693-707.
109. Yeo CJ, Cameron JL, Sohn TA et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997;226:248-257.
110. Sohn TA, Yeo CJ, Cameron JL et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567-579.
111. Schmidt CM, Powell ES, Yiannoutsos CT et al. Pancreaticoduodenectomy: a 20-year experience in 516 patients. Arch Surg 2004;139:718-725.
112. Fabre JM, Arnaud JP, Navarro F et al. Results of pancreatogastrostomy after pancreatoduodenectomy in 160 consecutive patients. Br J Surg 1998;85:751-754.
113. Schafer M, Mullhaupt B, Clavien PA. Evidence-based pancreatic head resection for pancreatic cancer and chronic pancreatitis. Ann Surg 2002;236:137-148.
114. Machado MC, Penteado S, Montagnini AL, Machado MA. An alternative technique in the treatment of celiac axis stenosis diagnosed during pancreaticoduodenectomy. HPB Surg 1998;10:371-373.
115. Yeo CJ, Barry MK, Sauter PK et al. Erythromycin accelerates gastric emptying after pancreaticoduodenectomy. A prospective, randomized, placebo-controlled trial. Ann Surg 1993;218:229-237.
116. Yeo CJ, Cameron JL, Maher MM et al. A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Ann Surg 1995; 222:580-588.
117. Suc B, Msika S, Fingerhut A et al. Temporary fibrin glue occlusion of the main pancreatic duct in the prevention of intra-abdominal complications after pancreatic resection: prospective randomized trial. Ann Surg 2003;237:57-65.
118. Sue B, Msika S, Piccinini M et al. Octreotide in the prevention of intra-abdominal complications following elective pancreatic resection: a prospective, multi-center randomized controlled trial. Arch Surg 2004;139:288-294.
119. Buchler MW, Friess H, Wagner M et al. Pancreatic fistula after pancreatic head resection. Br J Surg 2000;87:883-889.
120. Cullen JJ, Sarr MG, Ilstrup DM: Pancreatic anastomotic leak after pancreaticoduodenectomy: incidence, significance, and management. Am J Surg 1994;168:295-298.
121. Lemaire E, O'Toole D, Sauvanet A et al. Functional and morphological changes in the pancreatic remnant following pancreaticoduodenectomy with pancreaticogastric anastomosis. Br J Surg 2000;87:434-438.
122. Yamaguchi K, Tanaka M, Chijiiwa K et al. Early and late complications of pylorus-preserving pancreatoduodenectomy in Japan 1998. J Hepatobiliary Pancreat Surg 1999; 6:303-311.
123. Sakaguchi T, Nakamura S, Suzuki S et al. Marginal ulceration after pylorus-preserving pancreaticoduodenectomy. J Hepatobiliary Pancreat Surg 2000;7:193-197.
124. Horstmann O, Markus PM, Ghadimi MB, Becker H. Pylorus preservation has no impact on delayed gastric emptying after pancreatic head resection. Pancreas 2004;28:69-74.
125. Matthews BD, Smith TI, Kercher KW et al. Surgical experience with functioning pancreatic neuroendocrine tumors. Am Surg 2002;68:660-665.
126. Norton JA, Kivlen M, Li M et al. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg 2003;138:859-866.
127. Agarwal SK, Kester MB, Debelenko LV et al. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet 1997;6:1169-1175.
128. Veldhuis JD, Norton JA, Wells SA, Jr. et al. Surgical versus medical management of multiple endocrine neoplasia (MEN) type I. J Clin Endocrinol Metab 1997;82:357-364.
129. Ruszniewski P, Podevin P, Cadiot G et al. Clinical, anatomical, and evolutive features of patients with the Zollinger-Ellison syndrome combined with type I multiple endocrine neoplasia. Pancreas 1993;8:295-304.
130. Mignon M, Ruszniewski P, Podevin P et al. Current approach to the management of gastrinoma and insulinoma in adults with multiple endocrine neoplasia type I. World J Surg 1993;17:489-497.
131. Mignon M, Cadiot G. Diagnostic and therapeutic criteria in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. J Intern Med 1998;243:489-494.
132. Cadiot G, Vuagnat A, Doukhan I et al. Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Groupe d'Étude des Neoplasies Endocriniennes Multiples (GENEM and groupe de Recherche et d'Étude du Syndrome de Zollinger-Ellison (GRESZE). Gastroenterology 1999;116:286-293.
133. Mignon M, Cadiot G. Natural history of gastrinoma: lessons from the past. Ital J Gastroenterol Hepatol 1999;31 Suppl 2:S98-103.
134. Norton JA. Surgical treatment of gastrointestinal endocrine tumors. In Mignon M, Colombel JF (eds): "Recent Advances in the pathology and management of inflammatory bowel disease and digestive endocrine tumors." Paris: 1999;248-259.
135. Doherty GM, Doppman JL, Shawker TH et al. Results of a prospective strategy to diagnose, localize, and resect insulinomas. Surgery 1991;110:989-996.
136. Rothmund M, Angelini L, Brunt LM et al. Surgery for benign insulinoma: an international review. World J Surg 1990;14:393-398.
137. Proye C, Stalnikiewicz G, Wemeau JL et al. Genetically-driven or supposed genetic-related insulinomas in adults: validation of the surgical strategy proposed by the A.F.C.E./G.E.N.E.M.. Ann Endocrinol (Paris) 2004;65:149-161.
138. Sheppard BC, Norton JA, Doppman JL et al. Management of islet cell tumors in patients with multiple endocrine neoplasia: a prospective study. Surgery 1989;106:1108-1117.
139. Proye C, Pattou F, Carnaille B et al. Intraoperative insulin measurement during surgical management of insulinomas. World J Surg 1998;22:1218-1224.
140. O'Riordain DS, O'Brien T, van Heerden JA et al. Surgical management of insulinoma associated with multiple endocrine neoplasia type I. World J Surg 1994;18:488-493.
141. Lo CY, Lam KY, Fan ST. Surgical strategy for insulinomas in multiple endocrine neoplasia type I. Am J Surg 1998;175:305-307.
142. O'Riordain DS, O'Brien T, Grant CS et al. Surgical management of primary hyperparathyroidism in multiple endocrine neoplasia types 1 and 2. Surgery 1993;114:1031-1037.
143. Mignon M, Lamorthe B, Cadiot G. Zollinger-Ellison syndrome. Rev Prat 1994;44:1620-1628.
144. Bonnaud G, Cadiot G, Mignon M. [Diagnostic and therapeutic strategy of Zollinger-Ellison syndrome. Groupe de Recherches et d'Études du Syndrome de Zollinger-Ellison (GRESZE)]. Ann Chir 1994;48:535-546.
145. Herrmann ME, Ciesla MC, Chejfec G et al. Primary nodal gastrinomas. Arch Pathol Lab Med 2000;124:832-835.
146. Norton JA, Alexander HR, Fraker DL et al. Possible primary lymph node gastrinoma: occurrence, natural history, and predictive factors: a prospective study. Ann Surg 2003;237:650-657.
147. Stabile BE, Morrow DJ, Passaro E Jr. The gastrinoma triangle: operative implications. Am J Surg 1984;147:25-31.
148. Passaro E Jr, Howard TJ, Sawicki MP et al. The origin of sporadic gastrinomas within the gastrinoma triangle: a theory. Arch Surg 1998;133:13-16.
149. Sugg SL, Norton JA, Fraker DL et al. A prospective study of intraoperative methods to diagnose and resect duodenal gastrinomas. Ann Surg 1993;218:138-144.
150. Doherty GM, Olson JA, Frisella MM et al. Lethality of multiple endocrine neoplasia type I. World J Surg 1998;22:581-586.
151. Howard TJ, Zinner MJ, Stabile BE, Passaro E Jr. Gastrinoma excision for cure. A prospective analysis. Ann Surg 1990;211:9-14.
152. Soga J, Yakuwa Y. The gastrinoma/Zollinger-Ellison syndrome: statistical evaluation of a Japanese series of 359 cases. J Hepatobiliary Pancreat Surg 1998;5:77-85.
153. Lehy T, Cadiot G, Mignon M et al. Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. Gut 1992;33:1275-1279.
154. Cadiot G, Mignon M. Duodenopancreatic endocrine tumors in MEN I patients: influence on natural history and management. In Mignon M, Colombel JF (eds): "Recent advances in the pathophysiology and management of inflammatory bowel disease and digestive endocrine tumors." Paris: 1999:312-314.
155. Mignon M, Cadiot G. Importance of MEN I association in patients with digestive neuroendocrine tumors. Which screening to recommend? In Mignon M, Colombel JF (eds): "Recent advances in the pathophysiology and management of inflammatory bowel disease and digestive endocrine tumors." Paris: 1999;315-317.
156. Lairmore TC, Chen VY, DeBenedetti MK et al. Duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 2000;231:909-918.
157. Fraker DL, Norton JA. The role of surgery in the management of islet cell tumors. Gastroenterol Clin North Am 1989;18:805-830.
158. Lowney JK, Frisella MM, Lairmore TC, Doherty GM. Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: correlation with primary tumor size. Surgery 1998;124:1043-8, discussion.
159. Bartsch DK, Langer P, Wild A et al. Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance? Surgery 2000;128:958-966.
160. Skogseid B, Oberg K, Akerstrom G et al. Limited tumor involvement found at multiple endocrine neoplasia type I pancreatic exploration: can it be predicted by preoperative tumor localization? World J Surg 1998;22:673-677.
161. Thompson NW. Management of pancreatic endocrine tumors in patients with multiple endocrine neoplasia type 1. Surg Oncol Clin N Am 1998;7:881-891.
162. Thompson NW. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med 1998;243:495-500.
163. Cadiot G, Houillier P, Allouch A et al. Oral calcium tolerance test in the early diagnosis of primary hyperparathyroidism and multiple endocrine neoplasia type 1 in patients with the Zollinger-Ellison syndrome. Groupe de Recherche et d'Étude du Syndrome de Zollinger-Ellison. Gut 1996;39:273-278.
164. Brentjens R, Saltz L. Islet cell tumors of the pancreas: the medical oncologist's perspective. Surg Clin North Am 2001;81:527-542.
165. Tomassetti P, Migliori M, Lalli S et al. Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours. Ann Oncol 2001;12 Suppl 2:S95-S99.
166. Soga J, Yakuwa Y. Glucagonomas/diabetico-dermatogenic syndrome (DDS): a statistical evaluation of 407 reported cases. J Hepatobiliary Pancreat Surg 1998;5:312-319.
167. Guillausseau PJ, Guillausseau C, Villet R et al. Glucagonomas. Clinical, biological, anatomopathological and therapeutic aspects (general review of 130 cases. Gastroenterol Clin Biol 1982;6:1029-1041.
168. Boden G. Glucagonomas and insulinomas. Gastroenterol Clin North Am 1989;18:831-845.
169. Rothmund M, Stinner B, Arnold R. Endocrine pancreatic carcinoma. Eur J Surg Oncol 1991;17:191-199.
170. Chastain MA. The glucagonoma syndrome: a review of its features and discussion of new perspectives. Am J Med Sci 2001;321:306-320.
171. Mansour JC, Chen H. Pancreatic endocrine tumors. J Surg Res 2004; 120:139-161.
172. Bouin M, Aoust LD. Clinical response of an atypical glucagonoma treated with a long-acting somatostatin analog. Gastroenterol Clin Biol 2002;26:926-929.
173. Arnold R, Frank M, Kajdan U. Management of gastroenteropancreatic endocrine tumors: the place of somatostatin analogues. Digestion 1994;55 Suppl 3:107-113.
174. Eriksson B, Janson ET, Bax ND et al. The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours. Digestion 1996;57 Suppl 1:77-80.
175. Wermers RA, Fatourechi V, Kvols LK. Clinical spectrum of hyperglucagonemia associated with malignant neuroendocrine tumors. Mayo Clin Proc 1996;71:1030-1038.
176. Bloom SR, Polak JM, Welbourn RB. Pancreatic apudomas. World J Surg 1979;3:587-595.
177. Krejs GJ. VIPoma syndrome. Am J Med 1987;82:37-48.
178. Grier JF. WDHA (watery diarrhea, hypokalemia, achlorhydria) syndrome: clinical features, diagnosis, and treatment. South Med J 1995;88:22-24.
179. Peng SY, Li JT, Liu YB et al. Diagnosis and treatment of VIPoma in China: (case report and 31 cases review) diagnosis and treatment of VIPoma. Pancreas 2004;28:93-97.
180. Lundstedt C, Linjawi T, Amin T. Liver VIPoma: report of two cases and literature review. Abdom Imaging 1994;19:433-437.
181. Harris GJ, Tio F, Cruz AB, Jr. Somatostatinoma: a case report and review of the literature. J Surg Oncol 1987;36:8-16.
182. Masson B, Desfourneaux V, Raymond JM et al. Somatostatinome. A propos d'un cas. J Chir (Paris) 1997;134:22-26.
183. Hamy A, Heymann MF, Bodic J et al. [Duodenal somatostatinoma. Anatomic/ clinical study of 12 operated cases]. Ann Chir 2001;126:221-226.
184. Green BT, Rockey DC. Duodenal somatostatinoma presenting with complete somatostatinoma syndrome. J Clin Gastroenterol 2001;33:415-417.
185. House MG, Yeo CJ, Schulick RD. Periampullary pancreatic somatostatinoma. Ann Surg Oncol 2002;9:869-874.
186. Patel VG, Henderson VJ, Fairweather DA et al. Malignant duodenal somatostatinoma presenting in association with von Recklinghausen disease. Am Surg 2003;69:1077-1082.
187. Mao C, Shah A, Hanson DJ, Howard JM. Von Recklinghausen's disease associated with duodenal somatostatinoma: contrast of duodenal versus pancreatic somatostatinomas. J Surg Oncol 1995;59:67-73.
188. Berger G, Trouillas J, Bloch B et al. Multihormonal carcinoid tumor of the pancreas. Secreting growth hormone-releasing factor as a cause of acromegaly. Cancer 1984;54:2097-2108.
189. Losa M, von Werder K. Pathophysiology and clinical aspects of the ectopic GH-releasing hormone syndrome. Clin Endocrinol (Oxf) 1997;47:123-135.
190. Metz DC. Diagnosis of non-Zollinger-Ellison syndrome, non-carcinoid syndrome, enteropancreatic neuroendocrine tumours. Ital J Gastroenterol Hepatol 1999;31 Suppl 2:S153-S159.
191. Kaassis M, Duquenne M, Croue A et al. [Calcitonin-secreting neuroendocrine carcinoma of the pancreas with splenic invasion and paraneoplastic hypercalcemia]. Presse Med 2001;30:24.
192. Rankin W, Grill V, Martin TJ. Parathyroid hormone-related protein and hypercalcemia. Cancer 1997;80:1564-1571.
193. Abraham P, Ralston SH, Hewison M et al. Presentation of a PTHrP-secreting pancreatic neuroendocrine tumour, with hypercalcaemic crisis, pre-eclampsia, and renal failure. Postgrad Med J 2002;78:752-753.
194. Kitchens CS, Alexander RW. Cushing's syndrome secondary to a neuroendocrine tumor: relapse after bilateral adrenalectomy. Cancer 1981;48:1873-1876.
195. Ruszniewski P, Girard F, Benamouzig R et al. Long acting somatostatin treatment of paraneoplastic Cushing's syndrome in a case of Zollinger-Ellison syndrome. Gut 1988; 29:838-842.
196. Deixonne B, Duchene D, Eledjam JJ et al. Cancer du pancréas endocrine à EC-cell responsable d'une diarrhée chronique. J Chir 1991;128:415-418.
197. Mao C, el Attar A, Domenico DR et al. Carcinoid tumors of the pancreas. Status report based on two cases and review of the world's literature. Int J Pancreatol 1998;23:153-164.
198. Fleury A, Flejou JF, Sauvanet A et al. Calcitonin-secreting tumors of the pancreas: about six cases. Pancreas 1998;16:545-550.
199. Vinik AI, Strodel WE, Eckhauser FE et al. Somatostatinomas, PPomas, neurotensinomas. Semin Oncol 1987;14:263-281.
200. Bartsch DK, Schilling T, Ramaswamy A et al. Management of nonfunctioning islet cell carcinomas. World J Surg 2000;24:1418-1424.
201. Solorzano CC, Lee JE, Pisters PW et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 2001;130:1078-1085.
202. Simpson WF, Adams DB, Metcalf JS, Anderson MC. Nonfunctioning pancreatic neuroendocrine tumors presenting as pancreatitis: report of four cases. Pancreas 1988;3:223-231.
203. Madura JA, Cummings OW, Wiebke EA et al. Nonfunctioning islet cell tumors of the pancreas: a difficult diagnosis but one worth the effort. Am Surg 1997;63:573-577.
204. Nobels FR, Kwekkeboom DJ, Coopmans W et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997;82:2622-2628.
205. Park BJ, Alexander HR, Libutti SK et al. Operative management of islet-cell tumors arising in the head of the pancreas. Surgery 1998;124:1 056-1061.
206. Kianmanesh R, Farges O, Abdalla EK et al. Right portal vein ligation: a new planned two-step all-surgical approach for complete resection of primary gastrointestinal tumors with multiple bilateral liver metastases. J Am Coll Surg 2003;197:164-170.
207. Schnirer II, Yao JC, Ajani JA. Carcinoid - a comprehensive review. Acta Oncol 2003;42:672-692.
208. Oberg K, Eriksson B. Digestive endocrine tumor management ; medical advanced disease. In Mignon M, Colombel JF (eds): "Recent Advances in the pathology and management of inflammatory bowel disease and digestive endocrine tumors." Paris: 1999;260-270.
209. Shebani KO, Souba WW, Finkelstein DM et al. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 1999;229:815-821.
210. O'Toole D, Ducreux M, Bommelaer G et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000;88:770-776.
211. Jensen RT. Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment. Curr Opin Oncol 2000;12:368-377.
212. Goede AC, Winslet MC. Surgery for carcinoid tumours of the lower gastrointestinal tract. Colorectal Dis 2003;5:123-128.
213. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997;79:813-829.
214. Sandor A, Modlin IM. A retrospective analysis of 1570 appendiceal carcinoids. Am J Gastroenterol 1998; 93:422-428.
215. Goede AC, Caplin ME, Winslet MC. Carcinoid tumour of the appendix. Br J Surg 2003;90:1317-1322.
216. Rindi G, Capella C, Solcia E. Endocrine tumors of the stomach, intestine and appendix. In Mignon M, Colombel JF (eds): "Recent advances in the pathophysiology and management of inflammatory bowel disease and digestive endocrine tumors." Paris: 1999;274-277.
217. Rossi G, Valli R, Bertolini F et al. Does mesoappendix infiltration predict a worse prognosis in incidental neuroendocrine tumors of the appendix? A clinicopathologic and immunohistochemical study of 15 cases. Am J Clin Pathol 2003;120:706-711.
218. Roggo A, Wood WC, Ottinger LW. Carcinoid tumors of the appendix. Ann Surg 1993;217:385-390.
219. Yantiss RK, Odze RD, Farraye FA, Rosenberg AE. Solitary versus multiple carcinoid tumors of the ileum: a clinical and pathologic review of 68 cases. Am J Surg Pathol 2003;27:811-817.
220. Ballantyne GH, Savoca PE, Flannery JT et al. Incidence and mortality of carcinoids of the côlon. Data from the Connecticut Tumor Registry. Cancer 1992;69:2400-2405.
221. Simon SR, Fox K. Neuroendocrine carcinoma of the côlon. Correct diagnosis is important. J Clin Gastroenterol 1993;17:304-307.
222. Bernick PE, Klimstra DS, Shia J et al. Neuroendocrine carcinomas of the côlon and rectum. Dis Côlon Rectum 2004;47:163-169.
223. Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg Oncol 2003;12:153-172.
224. Modlin IM, Kidd M, Tang LH. Surgical management of gastric carcinoid tumors. In Mignon M, Colombel JF (eds): "Recent advances in the pathophysiology and management of inflammatory bowel disease and digestive endocrine tumors." Paris: 1999;341-343.
225. Lehy T, Roucayrol AM, Mignon M, Lewin MJ. Gastric carcinoid tumors in Zollinger-Ellison syndrome and pernicieuous anaemia: prevalence and biology. In Mignon M, Colombel JF (eds): "Recent advances in the pathophysiology and management of inflammatory bowel disease and digestive endocrine tumors." Paris: 1999;286-287.
226. Gilligan CJ, Lawton GP, Tang LH et al. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol 1995;90:338-352.
227. Lips CJ, Lentjes EG, Hoppener JW. The spectrum of carcinoid tumours and carcinoid syndromes. Ann Clin Biochem 2003;40:612-627.
228. Quaedvlieg PF, Lamers CB, Taal BG. Carcinoid heart disease: an update. Scand J Gastroenterol Suppl 2002:66-71.
229. Botero M, Fuchs R, Paulus DA, Lind DS. Carcinoid heart disease: a case report and literature review. J Clin Anesth 2002;14:57-63.
230. Anderson AS, Krauss D, Lang R. Cardiovascular complications of malignant carcinoid disease. Am Heart J 1997;134:693-702.
231. Vaughan DJ, Brunner MD. Anesthesia for patients with carcinoid syndrome. Int Anesthesiol Clin 1997;35:129-142.
232. Ruszniewski P, Ducreux M, Chayvialle JA et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 1996;39:279-283.
233. Arnold R. Medical treatment of metastasizing carcinoid tumors. World J Surg 1996;20:203-207.
234. Bax ND, Woods HF, Batchelor A, Jennings M. Octreotide therapy in carcinoid disease. Anticancer Drugs 1996;7 Suppl 1:17-22.
235. Ducreux M, Ruszniewski P, Chayvialle JA et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000;95:3276-3281.
236. Trendle MC, Moertel CG, Kvols LK. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. Cancer 1997;79:830-834.